Envestnet Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Envestnet Asset Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$601K	Buy	30,011 +15,805	+111%	+$279K	﹤0.01%	3949
2026 Q1	$231K	Buy	+14,206	New	+$237K	﹤0.01%	4431
2025 Q4	–	Sell	-10,301	Closed	-$160K	–	4546
2025 Q3	$160K	Sell	10,301 -1,500	-13%	-$20.5K	﹤0.01%	4362
2025 Q2	$151K	Buy	11,801 +743	+7%	+$9.16K	﹤0.01%	4290
2025 Q1	$140K	Buy	+11,058	New	+$150K	﹤0.01%	4198

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Envestnet Asset Management's HQL Position: Q2 2026 in Review

Envestnet Asset Management increased its abrdn Life Sciences Investors (HQL) stake by 111% in Q2 2026, buying an estimated $279K and bringing the position to 30,011 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #3949.

Envestnet Asset Management first reported a position in HQL in Q1 2025 and has held it in 5 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Envestnet Asset Management held 30,011 shares of abrdn Life Sciences Investors worth $601K as of Q2 2026.
Envestnet Asset Management bought 15,805 abrdn Life Sciences Investors shares in Q2 2026, an estimated $279K.
abrdn Life Sciences Investors made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3949 holding.
Envestnet Asset Management first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 5 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.